The GHD market is expanding through improved diagnostic capabilities and novel therapeutic formulations. Key players including Novo Nordisk, Pfizer, and Eli Lilly are developing long-acting growth hormone analogs and innovative delivery systems that enhance treatment adherence and patient outcomes. Advancements in diagnostic testing and treatment monitoring are optimizing management strategies for both pediatric and adult GHD populations. Access Market Report: https://shorturl.at/RdpJB